All In Biotech

Free tool

FAERS Monitor: Uplizna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761142 or its brand name (Uplizna, Inebilizumab-Cdon). Reports on generic versions are filed under their own applications.

Reports

858

Serious

625

73% of reports

Hospitalization

303

Death reported

53

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neuromyelitis optica spectrum disorder130
  • off label use76
  • headache50
  • urinary tract infection44
  • fatigue39
  • nausea38
  • myasthenia gravis37
  • pneumonia36
  • covid-1932
  • pain31
  • arthralgia25
  • death23
  • pyrexia23
  • infection21
  • hypoaesthesia20

Reports by year received

View as table
YearReports
202021
202179
202222
202350
2024143
2025161
2026382

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,301 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuromyelitis optica spectrum disorderSignal1302616.82212.1304,828
myasthenia gravisSignal37112.882.23,973
urinary tract infectionSignal446.34.7193
covid-19Signal324.53.283
infectionSignal213.62.336
hypoaesthesiaSignal203.32.130
pneumoniaSignal362.72.038
off label useSignal762.11.746
headache502.01.523
pyrexia231.61.15
arthralgia251.51.03
pain311.20.91
fatigue391.20.91
nausea381.20.91
death230.70.44

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.